Difference between revisions of "Tendering process for pneumococcal conjugate vaccine"
m |
|||
| Line 4: | Line 4: | ||
{{summary box | {{summary box | ||
|question = <span style="float: right; margin-right: 10px;">[[Image:Thl logo.png]]</span> How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine in Finland? | |question = <span style="float: right; margin-right: 10px;">[[Image:Thl logo.png]]</span> How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine in Finland? | ||
| − | |answer = To answer this question, [[THL]] is organising an open discussion during summer 2014. The outcome recommendation of this process is given to the National Immunization Technical Advisory Group and the Ministry of Social Affairs and Health in September. The discussion is focussed on three topics: | + | |answer = To answer this question, [[THL]] is organising an open discussion during summer 2014. The outcome recommendation of this process is given to the National Immunization Technical Advisory Group (NITAG) and the Ministry of Social Affairs and Health in September. The discussion is focussed on three topics: |
* [[Comparison criteria|What criteria should be used when comparing vaccines?]] | * [[Comparison criteria|What criteria should be used when comparing vaccines?]] | ||
* [[Epidemiological modelling|How should different health effects be compared?]] | * [[Epidemiological modelling|How should different health effects be compared?]] | ||
| Line 13: | Line 13: | ||
# Sign in Opasnet and participate by editing the talk pages of any substance page. Participants must obey these rules: [[Help:Editing]]. Some discussion are organised, see instructions for [[discussion]]. | # Sign in Opasnet and participate by editing the talk pages of any substance page. Participants must obey these rules: [[Help:Editing]]. Some discussion are organised, see instructions for [[discussion]]. | ||
| − | You should first browse the pneumococcus assessment pages so that you can give your comments on a right page and whether your comment has actually been raised already. Comments are not repeated, and irrelevant comments will be removed. All relevant content will stay on the pages. Please note, however, that other participants may try to prove your comments false; if proven false, your comments as such will not be reflected in the final recommendation that is given to the Ministry of Social Affairs and Health. | + | You should first browse the pneumococcus assessment pages so that you can give your comments on a right page and whether your comment has actually been raised already. Comments are not repeated, and irrelevant comments will be removed. All relevant content will stay on the pages. Please note, however, that other participants may try to prove your comments false; if proven false, your comments as such will not be reflected in the final recommendation that is given to NITAG and the Ministry of Social Affairs and Health. |
See additional information about [[Pneumococcal vaccine products]]. | See additional information about [[Pneumococcal vaccine products]]. | ||
| Line 26: | Line 26: | ||
* We restrict the analysis to vaccination within the infant immunisation programme. | * We restrict the analysis to vaccination within the infant immunisation programme. | ||
* We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: [[:op_fi:Vertailuperusteet|Vertailuperusteet]]). | * We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: [[:op_fi:Vertailuperusteet|Vertailuperusteet]]). | ||
| − | * The aim is to prepare selection criteria that | + | * The aim is to prepare selection criteria that enables to choose economically the most advantageous tender. |
* We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis. | * We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis. | ||
* The preparation of the criteria is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines. | * The preparation of the criteria is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines. | ||
| − | * The procurement can only involve a product that has | + | * The procurement can only involve a product that has marketing authorization in EU/Finland (see [http://www.finlex.fi/fi/laki/ajantasa/1987/19870395/#L4P20a Lääkelain 20a§]). |
* The procurement must follow the Act on Public Procurement ([http://www.finlex.fi/fi/laki/ajantasa/2007/20070348 julkisista hankinnoista annetun lain] mukainen). | * The procurement must follow the Act on Public Procurement ([http://www.finlex.fi/fi/laki/ajantasa/2007/20070348 julkisista hankinnoista annetun lain] mukainen). | ||
| − | * The discussion on these pages | + | * The discussion on these pages is not binding to the preparation of the procurement. |
== Answer == | == Answer == | ||
| − | A preliminary answer is to focus on effectiveness to reduce serious pneumococcal | + | A preliminary answer is to focus on effectiveness to reduce serious pneumococcal diseases and the economic effectiveness of the vaccines. |
== Rationale == | == Rationale == | ||
Revision as of 10:43, 8 July 2014
This page is a assessment.
The page identifier is Op_en6352 |
|---|
| Moderator:Jouni (see all) |
|
Give your opinion to the peer rating of the content of this page. |
| Upload data
|
| Main message: |
|---|
| Question:
Error creating thumbnail: Unable to save thumbnail to destination How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine in Finland?
To answer this question, THL is organising an open discussion during summer 2014. The outcome recommendation of this process is given to the National Immunization Technical Advisory Group (NITAG) and the Ministry of Social Affairs and Health in September. The discussion is focussed on three topics:
You can participate in two ways:
You should first browse the pneumococcus assessment pages so that you can give your comments on a right page and whether your comment has actually been raised already. Comments are not repeated, and irrelevant comments will be removed. All relevant content will stay on the pages. Please note, however, that other participants may try to prove your comments false; if proven false, your comments as such will not be reflected in the final recommendation that is given to NITAG and the Ministry of Social Affairs and Health. See additional information about Pneumococcal vaccine products. |
Contents
Question
How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine?
Scope
- We restrict the analysis to vaccination within the infant immunisation programme.
- We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: Vertailuperusteet).
- The aim is to prepare selection criteria that enables to choose economically the most advantageous tender.
- We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis.
- The preparation of the criteria is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines.
- The procurement can only involve a product that has marketing authorization in EU/Finland (see Lääkelain 20a§).
- The procurement must follow the Act on Public Procurement (julkisista hankinnoista annetun lain mukainen).
- The discussion on these pages is not binding to the preparation of the procurement.
Answer
A preliminary answer is to focus on effectiveness to reduce serious pneumococcal diseases and the economic effectiveness of the vaccines.
Rationale
The rationale has been summarised in the following 3 pages: Vertailuperusteet (in Finnish), Epidemiological modelling ja Taloudellinen arviointi (in Finnish).
Comparison of vaccine products will be based on their price and expected health benefits (in Finnish: vertailuperusteet). The health benefits mean the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the benefits is realised by using an epidemiological model. The effectiveness of the vaccination programme will be quantified as the expected improvement in health-associated quality of life. The selection criterion is formulated so that the economically most advantageous product will be chosen (in Finnish: taloudellisen arvioinnin).
See also
